论文部分内容阅读
目的观察小剂量尿激酶联合降纤酶治疗急性脑梗死的疗效。方法将我院2008年12月-2010年12月收治的96例急性脑梗死患者随机分为治疗组48例和对照组48例,两组均给予降颅内压、扩血管治疗、应用抗血小板药物、维持水电解质平衡及营养支持等常规治疗,治疗组在此基础上联合使用小剂量尿激酶和降纤酶治疗,两组疗程均为14 d。结果治疗3 d后治疗组的神经功能缺损评分较治疗前有明显下降(P<0.05),而对照组无统计学意义(P>0.05);治疗l4 d后治疗组的神经功能缺损评分明显优于对照组,差异有统计学意义(P<0.05);治疗组的临床疗效明显高于对照组(P<0.05)。结论小剂量尿激酶联合降纤酶治疗急性脑梗死的疗效显著,且治疗过程中无明显不良反应,值得临床推广应用。
Objective To observe the efficacy of low-dose urokinase combined with defibrase in the treatment of acute cerebral infarction. Methods A total of 96 patients with acute cerebral infarction who were treated in our hospital from December 2008 to December 2010 were randomly divided into treatment group (48 cases) and control group (48 cases). Both groups were given intracranial pressure lowering and vasodilator therapy. Antiplatelet Drugs, maintaining water and electrolyte balance and nutritional support and other conventional treatment, the treatment group on the basis of combination of low-dose urokinase and defibrase treatment, the two groups of treatment were 14 d. Results After 3 days of treatment, the score of neurological deficit in the treatment group was significantly lower than that before treatment (P <0.05), but there was no significant difference in the control group (P> 0.05). The score of neurological deficit in the treatment group was obviously superior to that of the control group In the control group, the difference was statistically significant (P <0.05). The clinical efficacy of the treatment group was significantly higher than that of the control group (P <0.05). Conclusion The combination of low-dose urokinase and defibrase has a significant therapeutic effect on acute cerebral infarction. There is no obvious adverse reaction during the treatment, which is worthy of clinical application.